Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02152761 · ClinicalTrials.gov registry record · Phase 2
Study of Efficacy and Safety of Bimagrumab in Patients After Hip Fracture Surgery
A Phase 2 study of Muscle Wasting (Atrophy) After Hip Fracture Surgery, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 251
- Enrollment target
- 20
- Study locations
NCT02152761 is a Phase 2 study of Muscle Wasting (Atrophy) After Hip Fracture Surgery that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 251 participants. The trial reports 20 study locations across 10 states.
The verdict
NCT02152761, a Phase 2 study of Muscle Wasting (Atrophy) After Hip Fracture Surgery, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 251 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study was to assess if bimagrumab is safe and effective in patients with muscle wasting (atrophy) after hip fracture surgery.
Conditions Studied
Interventions
- OTHER placebo
- DRUG bimagrumab
Study Locations (20)
Other
- Novartis Investigative Site - Ciudad Autonoma de Bs As
- Novartis Investigative Site - Graz
- Novartis Investigative Site - Bruges
- Novartis Investigative Site - Genk
- Novartis Investigative Site - Ghent
- Novartis Investigative Site - Santiago
- Novartis Investigative Site - Barranquilla
Czech Republic
- Novartis Investigative Site - Brno
- Novartis Investigative Site - Hradec Králové
- Novartis Investigative Site - Pardubice
- Novartis Investigative Site - Pilsen
- Novartis Investigative Site - Prague
Arizona
- Novartis Investigative Site - Phoenix
California
- Novartis Investigative Site - El Cajon
Colorado
- Novartis Investigative Site - Denver
Georgia
- Novartis Investigative Site - Gainesville
Minnesota
- Novartis Investigative Site - Rochester
New York
- Novartis Investigative Site - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 251 participants |
| Start Date | 2014-09-16 |
| Est. Completion | 2018-10-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02152761
The ClinicalTrials.gov registry entry for NCT02152761 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 251 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Muscle Wasting (Atrophy) After Hip Fracture Surgery appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT02152761 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Other, Czech Republic, Arizona.
Frequently Asked Questions
What is clinical trial NCT02152761 about?
NCT02152761 is a clinical study titled "Study of Efficacy and Safety of Bimagrumab in Patients After Hip Fracture Surgery". The purpose of this study was to assess if bimagrumab is safe and effective in patients with muscle wasting (atrophy) after hip fracture surgery.
What is the current status of trial NCT02152761?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 251 participants. The study started on 2014-09-16. Estimated completion is 2018-10-25.
What conditions does trial NCT02152761 study?
This clinical trial studies the following conditions: Muscle Wasting (Atrophy) After Hip Fracture Surgery.
What interventions are being tested in trial NCT02152761?
The interventions under investigation include: placebo (OTHER), bimagrumab (DRUG).
Who is sponsoring clinical trial NCT02152761?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02152761 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Georgia, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.